Biochemical and Biophysical Research Communications
Regular ArticleHighly Potent Nociceptin Analog Containing the Arg-Lys Triple Repeat☆
References (43)
- et al.
FEBS Lett.
(1994) - et al.
FEBS Lett.
(1994) - et al.
FEBS Lett.
(1994) - et al.
Biochem. Biophys. Res. Commun.
(1994) - et al.
Mol. Brain Res.
(1996) - et al.
J. Biol. Chem.
(1996) - et al.
Eur. J. Pharmacol.
(1997) - et al.
J. Biol. Chem.
(1994) - et al.
Peptides
(1998) - et al.
J. Biol. Chem.
(1996)
Life Sci.
FEBS Lett.
J. Biol. Chem.
Eur. J. Med. Chem.
J. Biol. Chem.
Tetrahedron Lett.
Nature
Science
Proc. Natl. Acad. Sci. USA
Biochem. J.
Eur. J. Neurosci.
Cited by (78)
Receptor-binding affinities of bisphenol A and its next-generation analogs for human nuclear receptors
2019, Toxicology and Applied PharmacologyCitation Excerpt :This was completely different from the binding assay of G protein-coupled receptor (GPCR) proteins. For instance, the binding assay for GPCR opioid receptors δ, μ, κ, and opioid receptor-like 1 (ORL1) nociceptin receptor, the protein molecules of which are independent of each other, can be performed under the same assay conditions (Okada et al., 2000). One of the intrinsic differences between the NR and GPCR proteins is their localization.
Structure activity studies of nociceptin/orphanin FQ(1-13)-NH<inf>2</inf> derivatives modified in position 5
2015, Bioorganic and Medicinal ChemistryCitation Excerpt :These NOP ligands have been extensively investigated and characterized in several in vitro and in vivo assays.16 In parallel, the replacement of position 14 and 15 with a couple of Arg-Lys residues in the natural peptide sequence or in the NOP antagonist peptide [Nphe1]N/OFQ-NH2 generated highly potent NOP ligands acting as agonist17,18 and antagonist,19 respectively. This suggests that the C-terminal part of the peptide is important for NOP receptor occupation.
Helix-Constrained Nociceptin Peptides Are Potent Agonists and Antagonists of ORL-1 and Nociception
2015, Vitamins and HormonesCitation Excerpt :As suggested above, the improvement in activity is likely due to the induction of α-helicity, rather than solely amino acid substitution. Similar enhancement of agonist activity between compounds 6 and 17 (compared to 2 and 12, respectively) has been reported previously (Arduin et al., 2007; Bigoni et al., 2002; Guerrini, Calo, Bigoni, Rizzi, Regoli, et al., 2001; Guerrini et al., 2005; Okada et al., 2000). Compound 12 (18 amino acids) could not be truncated to a monocyclic analogue (14, 13 amino acids) and retain agonist activity.
Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs
2013, Pharmacology and TherapeuticsSpare interactions of highly potent [Arg<sup>14</sup>,Lys<sup>15</sup>]nociceptin for cooperative induction of ORL1 receptor activation
2009, Bioorganic and Medicinal Chemistry
- ☆
Abbreviations used: GTPγS, guanosine 5′-(γ-thio)triphosphate; ORL1, opioid receptor-like 1; RK, Arg-Lys; RP-HPLC, reversed-phase high-performance liquid chromatography; SPA, scintillation proximity assay.
- 1
To whom correspondence should be addressed. Fax: +81-92-642-2584. E-mail: [email protected].